← Compound Library

Lanreotide

Somatostatin Analog

Also known as: Somatuline Autogel · Somatuline Depot

A long-acting somatostatin analog administered as a deep subcutaneous depot every 4 weeks. Approved for acromegaly & gastroenteropancreatic neuroendocrine tumors.

Typical Dose

60–120 mg every 4 weeks (deep SubQ depot)

Route

Deep subcutaneous injection

Cycle

Monthly ongoing

Half-life

~23–30 days (depot release)

Storage

2–8°C.

Overview

Lanreotide is a synthetic somatostatin analog available as an extended-release depot (Somatuline Autogel) administered every 4 weeks by deep SubQ injection. It has similar receptor binding to octreotide (SSTR2 & SSTR5) but different formulation characteristics.

Quick Start Guide

1

Physician-administered deep SubQ depot injection every 4 weeks.

Research Indications

Acromegaly

Most Effective

FDA approved. Reduces GH & IGF-1.

GEP-NETs

Most Effective

FDA approved for unresectable, well/moderately differentiated neuroendocrine tumors. Antiproliferative effect.

Side Effects & Safety

Common

  • GI effects
  • Gallstones
  • Injection site pain
  • Hyperglycemia

Uncommon

  • Bradycardia
  • Hypothyroidism

When to Stop

  • Symptomatic gallstones
  • Signs of allergic reaction

How to Reconstitute

1

Pre-filled syringe — no reconstitution. Physician-administered.

Dosing math: Clinical product.

Quality Indicators

Good — use as normal

  • Per manufacturer

Discard immediately

  • Per manufacturer

What to Expect

Month 1

GH suppression begins. NET growth stabilization expected.

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.

Submit a sample